BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 16580495)

  • 1. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
    Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary results of bladder-preserving therapy with definitive radiotherapy and intraarterial infusion of chemotherapy.
    Tsujii H; Akaza H; Ohtani M; Miyanaga N; Shimazoi T; Uchida K; Koiso K; Tsuji H; Okumura T; Ohara K
    Strahlenther Onkol; 1994 Sep; 170(9):531-7. PubMed ID: 7940124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
    Freiha F; Reese J; Torti FM
    J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy.
    Chauvet B; Brewer Y; Félix-Faure C; Davin JL; Choquenet C; Reboul F
    J Urol; 1996 Oct; 156(4):1258-62. PubMed ID: 8808849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polychemotherapy in advanced bladder cancer. Practicality and clinical results].
    Klän R; Knispel H; Huland H
    Urologe A; 1992 Jul; 31(4):247-50. PubMed ID: 1514213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
    Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic chemotherapy for muscle invasive bladder cancer.
    Ondrus D; Hornák M; Bárdos A; Ondrus B
    Neoplasma; 1994; 41(5):263-8. PubMed ID: 7854496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective bladder preservation by combination treatment of invasive bladder cancer.
    Kaufman DS; Shipley WU; Griffin PP; Heney NM; Althausen AF; Efird JT
    N Engl J Med; 1993 Nov; 329(19):1377-82. PubMed ID: 8413433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intra-arterial chemotherapy with cisplatin in advanced urothelial cancer].
    Takahashi Y; Uno H; Nagai T; Tamaki M; Nagatani Y; Shinoda I; Takeuchi T; Fujihiro S; Kuriyama M; Kawada Y
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2806-9. PubMed ID: 2782890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience].
    González Enguita C; Caro Cebrián C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Rioja Sanz LA
    Arch Esp Urol; 1990; 43 Suppl 2():197-204. PubMed ID: 2096779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
    Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M; Kotake T
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
    J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.
    Koch MO; Coussens D
    Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122
    [No Abstract]   [Full Text] [Related]  

  • 18. Extended experience of neo-adjuvant M-VAC chemotherapy for T1-4 N0 M0 transitional cell carcinoma of the urinary bladder.
    Keating JP; Zincke H; Hahn RG; Morgan WR
    Prog Clin Biol Res; 1990; 353():119-27. PubMed ID: 2217409
    [No Abstract]   [Full Text] [Related]  

  • 19. [Is down-staging of advanced bladder cancer by neoadjuvant chemotherapy possible?--MVEC protocol].
    Hoch V; Noll F; Schreiter F
    Urologe A; 1992 Jul; 31(4):243-6. PubMed ID: 1514212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for bladder cancer.
    Hrushesky WJ; Roemeling RV; Wood PA; Langevin TR; Lange P; Fraley E
    Cancer Treat Rep; 1987 Oct; 71(10):915-9. PubMed ID: 3652055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.